MTS105 / METiS Pharmaceuticals - LARVOL DELTA

Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. (PubMed, Nat Commun) - "No severe adverse effects or gross pathology were observed. Our results thus support the advancement of MTS105 into clinical trials, with a first-in-human study currently underway."

Journal • Hematological Disorders • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • GPC3

Preclinical development of an mRNA-encoded T cell engager targeting Glypican-3 with tissue- and tumor-specific enrichment in hepatocellular carcinoma (AACR 2025) - "The mRNA was encapsulated in a novel lipid nanoparticle (LNP) for efficient liver-tropic delivery, forming the complex named MTS105... The mRNA-encoded TCE demonstrated optimal tissue/tumor-specific PK, safety and potent anti-tumor activity in preclinical models. These preclinical studies enabled a first-in-human study to assess its safety and preliminary efficacy which is currently ongoing."

Preclinical • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • GPC3